Voyager Therapeutics (VYGR) Liabilities and Shareholders Equity (2014 - 2026)
Voyager Therapeutics recorded quarterly Liabilities and Shareholders Equity of $219.3 million in Q1 2026, down 13.06% quarter-over-quarter from $252.3 million in Q4 2025, and down 37.91% year-over-year from $353.2 million in Q1 2025.
Voyager Therapeutics' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $219.3 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 37.91% year-over-year to $219.3 million; the TTM figure through Mar 2026 stood at $1.1 billion (down 32.73% YoY), while the FY2025 annual figure was $252.3 million, down 35.81% from the prior year.
- Liabilities and Shareholders Equity came in at $219.3 million for Q1 2026 at Voyager Therapeutics, down from $252.3 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $469.6 million in Q1 2024 to a low of $159.4 million in Q4 2022.
- A 5-year average of $306.6 million and a median of $315.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity jumped 120.44% in 2023 and plunged 37.91% in 2026, its largest moves.
- Voyager Therapeutics' Liabilities and Shareholders Equity stood at $159.4 million in 2022, then surged by 120.44% to $351.3 million in 2023, then advanced by 11.89% to $393.0 million in 2024, then tumbled by 35.81% to $252.3 million in 2025, then retreated by 13.06% to $219.3 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $219.3 million, $252.3 million, and $288.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Voyager Therapeutics | 230.25 Mn | 88.77 Mn | - | 219.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 219.33 Mn |
| Dec 31, 2025 | 252.28 Mn |
| Sep 30, 2025 | 288.31 Mn |
| Jun 30, 2025 | 322.10 Mn |
| Mar 31, 2025 | 353.24 Mn |
| Dec 31, 2024 | 393.05 Mn |
| Sep 30, 2024 | 426.04 Mn |
| Jun 30, 2024 | 436.23 Mn |
| Mar 31, 2024 | 469.59 Mn |
| Dec 31, 2023 | 351.28 Mn |
| Sep 30, 2023 | 294.65 Mn |
| Jun 30, 2023 | 315.54 Mn |
| Mar 31, 2023 | 336.29 Mn |
| Dec 31, 2022 | 159.36 Mn |
| Sep 30, 2022 | 182.48 Mn |
| Jun 30, 2022 | 188.61 Mn |
| Mar 31, 2022 | 224.18 Mn |
| Dec 31, 2021 | 193.86 Mn |
| Sep 30, 2021 | 184.77 Mn |
| Jun 30, 2021 | 208.73 Mn |
| Mar 31, 2021 | 237.72 Mn |
| Dec 31, 2020 | 261.58 Mn |
| Sep 30, 2020 | 269.76 Mn |
| Jun 30, 2020 | 297.46 Mn |
| Mar 31, 2020 | 322.61 Mn |
| Dec 31, 2019 | 354.76 Mn |
| Sep 30, 2019 | 376.22 Mn |
| Jun 30, 2019 | 388.59 Mn |
| Mar 31, 2019 | 411.35 Mn |
| Dec 31, 2018 | 177.03 Mn |
| Sep 30, 2018 | 197.06 Mn |
| Jun 30, 2018 | 214.66 Mn |
| Mar 31, 2018 | 235.03 Mn |
| Dec 31, 2017 | 184.48 Mn |
| Sep 30, 2017 | 140.92 Mn |
| Jun 30, 2017 | 158.41 Mn |
| Mar 31, 2017 | 175.09 Mn |
| Dec 31, 2016 | 189.57 Mn |
| Sep 30, 2016 | 201.98 Mn |
| Jun 30, 2016 | 209.82 Mn |
| Mar 31, 2016 | 219.98 Mn |
| Dec 31, 2015 | 229.46 Mn |
| Sep 30, 2015 | 166.44 Mn |
| Dec 31, 2014 | 11.50 Mn |